RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas

MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Selected sarcoma subtypes are being treated with Trabectedin in second line, which promotes DNA damage and p53-dependent apoptosis. The aim of this study was to evaluate the improvement of Trabectedin response with MDM2 inhib...

Full description

Saved in:
Bibliographic Details
Published inCancer investigation Vol. 33; no. 9; pp. 440 - 450
Main Authors Obrador-Hevia, Antònia, Martinez-Font, Esther, Felipe-Abrio, Irene, Calabuig-Fariñas, Silvia, Serra-Sitjar, Margalida, López-Guerrero, José Antonio, Ramos, Rafael, Alemany, Regina, Martín-Broto, Javier
Format Journal Article
LanguageEnglish
Published England Informa Healthcare 21.10.2015
Subjects
Liposarcoma
MDM2
RG7112
Soft tissue sarcomas
Trabectedin
MDM2
Trabectedin
Soft tissue sarcomas
Liposarcoma
RG7112
Online AccessGet full text

Cover

More Information
Summary:MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Selected sarcoma subtypes are being treated with Trabectedin in second line, which promotes DNA damage and p53-dependent apoptosis. The aim of this study was to evaluate the improvement of Trabectedin response with MDM2 inhibitors in soft tissue sarcomas. The antitumor effects of Trabectedin, Nutlin-3A and RG7112 as single agents or in combination were examined in vitro. RG7112 significantly synergized with Trabectedin in MDM2-amplified liposarcoma cells, representing a promising new therapeutic strategy for the treatment of sarcomas with MDM2 amplification.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0735-7907
1532-4192
DOI:10.3109/07357907.2015.1064534